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Abstract
Background: The amino acid composition of a low molecular weight chromium binding peptide
(LMWCr), isolated from bovine liver, is reportedly E:G:C:D::4:2:2:2, though its sequence has not
been discovered. There is some controversy surrounding the exact biochemical forms and the
action of Cr(III) in biological systems; the topic has been the subject of many experimental reports
and continues to be investigated. Clarification of Cr-protein interactions will further understanding
Cr(III) biochemistry and provide a basis for novel therapies based on metallocomplexes or small
molecules.
Results: A genomic search of the non-redundant database for all possible decapeptides of the
reported composition yields three exact matches, EDGEECDCGE, DGEECDCGEE and
CEGGCEEDDE. The first two sequences are found in ADAM 19 (A Disintegrin and
Metalloproteinase domain 19) proteins in man and mouse; the last is found in a protein kinase in
rice (Oryza sativa). A broader search for pentameric sequences (and assuming a disulfide dimer)
corresponding to the stoichiometric ratio E:D:G:C::2:1:1:1, within the set of human proteins and
the set of proteins in, or related to, the insulin signaling pathway, yields a match at an acidic region
in the α-subunit of the insulin receptor (-EECGD-, residues 175–184). A synthetic peptide derived
from this sequence binds chromium(III) and forms a metal-peptide complex that has properties
matching those reported for isolated LMWCr and Cr(III)-containing peptide fractions.
Conclusion: The search for an acidic decameric sequence indicates that LMWCr may not be a
contiguous sequence. The identification of a distinct pentameric sequence in a significant insulin-
signaling pathway protein suggests a possible identity for the LMWCr peptide. This identification
clarifies directions for further investigation of LMWCr peptide fractions, chromium bio-
coordination chemistry and a possible role in the insulin signaling pathway. Implications for models
of chromium action in the insulin-signaling pathway are discussed.
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Background
Type II diabetes continues to grow as a worldwide epi-
demic; it is expected that this disease will surpass 300 mil-
lion cases by 2025 [1-5]. Understanding the complex
signaling mechanisms of insulin receptor and down-
stream factors, e.g. IRS1 and IRS2 [6], is crucial in the
design of effective therapeutic strategies. Clarification of
such signaling mechanisms is expected to lead to discov-
eries to cure or prevent diabetes and other metabolic con-
ditions [1]. Current strategies include the search for small
synthetic or naturally-derived molecules to act upstream
of IRS1, to adequately compensate for insulin dysregula-
tion [7,8]. One unknown facet in this complex problem is
the role that chromium may play in the regulation of glu-
cose metabolism; the molecular basis of chromium action
in biological systems has not been definitively explained
[9,10]. While the toxicology Cr(VI) has been well charac-
terized [11], an understanding of the biochemistry and
action of Cr(III) continues to elude researchers within this
field [9,11-18]. The lack of good mechanistic models and
experiments currently limits researchers' ability to assess
the relative importance of Cr(III) and its possible roles in
glucose metabolism, obesity or Type II diabetes. Recently,
a Cr-peptide fraction isolated from bovine liver [19-23]
was shown to potentiate the action of insulin. The amino
acid composition of this "low molecular weight Cr" com-
plex (LMWCr, containing 3–4 chromic atoms) was identi-
fied to be approximately E:G:C:D::4:2:2:2 [18,21,24],
though the sequence remains unknown (Figure 1) and
there appears to be some difficulty in exactly repeating
this work. Although not specifically related to Cr(III)
metabolism, Ramasami and co-workers report that Cr(III)
induces structural changes and long range ordering in col-
lagenous tissues and suggest the formation of multinu-
clear Cr-oxo and hydroxo clusters (2, 3, or 4 Cr atoms)
holding the proteinaceous molecular assembly together
[25,26]. In this study, we report on a bioinformatics
search for the LMWCr peptide, and propose that the pep-
tide that binds to Cr(III) may be the pentameric sequence
(-EECGD-) as it is found within the insulin receptor
(INSR; Swiss-Prot: P06213) (-NKDDNEECGD-, residues
175–184) and conforms to the predicted stoichiometry.
Further, visible absorption data and electron paramag-
netic measurements of the synthesized disulfide linked
dimeric Cr-peptide complex are identical to that of the
biologically isolated fractions.
Results
Genomic search for LMWCr
Recent reports [18,21,24], using extracts from bovine
liver, suggest that LMWCr is of peptide origin, having an
approximate stoichiometric ratio consisting of
E:D:G:C::4:2:2:2. In the absence of the exact sequence of
this peptide, we generated all possible permutations
matching the reported stoichiometry of LMWCr (10!/
4!2!2!2! = 18,900) and performed an exact match search
of the non-redundant (nr) protein database for their
occurrence. Based on a simple model where all amino
acids are equally possible and about 1.5 million
sequences of average length 200 present in the nr data-
base, the E-value for an independent exact match is about
0.55 [(0.05)10 * 200 * 1.5 * 106 * 18,900].
We found perfect matches in the nr database correspond-
ing to 3 unique permutations: EDGEECDCGE, DGEECD-
CGEE and CEGGCEEDDE. One match, CEGGCEEDDE,
was found only in one sequence annotated as a putative
protein kinase in rice (Oryza sativa). The peptide
sequences, EDGEECDCGE and DGEECDCGEE, both
matched the same region of the disintegrin domain of the
human and mouse versions of ADAM 19 (A Disintegrin
and Metalloproteinase domain 19; GeneID: 8728) [27].
Since the bovine form of ADAM 19 has yet to be
sequenced, we were unable to determine if this sequence
is also present in bos taurus. This acid-rich sequence region
(Table 1) is present at the beginning of the disintegrin
domain of ADAM19 [27]. We note that the DNA coding
location for this subsequence is at the very end of an exon,
giving rise to the speculation that the decameric peptide
could possibly be an alternative splicing product. Argu-
ments against this sequence giving rise to LMWCr and the
Hypothetical models of low-molecular weight Cr peptide complexesFigur  1
Hypothetical models of low-molecular weight Cr peptide 
complexes.
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complex acting intracellulary are that ADAM 19 is a mem-
brane protein with extracellular domains. This argument
is not needed if Cr might act extracellularly; the conserved
nature of the motif leads one to suspect that it plays an
important role, but it is at best a highly tentative candidate
for being LMWCr. From these results, LMWCr appears
unlikely to be a contiguous peptide sequence, unless an
as-yet undiscovered peptide is found.
Noting that the reported stoichiometry consists of even
numbers of amino acids, we further considered the possi-
bility that LMWCr might be a disulfide-linked dimer, with
each monomeric unit having the composition,
E:D:G:C::2:1:1:1. Such a hypothesis is consistent with the
limited resolution of the experimental data used to derive
the stoichiometry [24] and yields 60 sequence permuta-
tions. The expected number of random matches in the nr
database is much higher, ~104. Restricting this search to
the human proteome gave rise to 439 (expected: ~102)
matches, with no reason to prefer one over the other.
Insulin signaling pathway mapping
Considering that LMWCr might be a subsequence of a
protein related to "insulin" or known to be involved in
the insulin signalling pathway, we compiled a set of 96
such sequences. This set comprised two components: 1)
proteins playing a role in the insulin signaling pathway
(23 protein sequences were selected) derived from path-
way charts, and 2) the set of all protein sequences derived
from SwissProt for the search, "insulin + human" (78
entries). The two components were compared for redun-
dancy and the duplicates removed (5 instances).
A cross comparison of the resulting 439 entries using the
BLAST query method versus the set of 96 pathway and
insulin-related proteins results in a unique match for one
of the 60 pentapeptides, EECGD, within the insulin recep-
tor (INSR), residues 180–184 (expected matches: ~10-1).
Comparison of the pentapeptide set to a more detailed
insulin signaling pathway construct [28] yielded the same
result.
This sub-sequence lies in the extracellular α-subunit of
INSR in an acid-rich region (-NKDDNEECGD-) towards
the end of the L1 domain, and at the start of the "cysteine-
rich region". A BLAST query [29] for all INSR homologs in
the nr database shows that this sub-sequence and acidic
region is conserved in mouse and rat. Given the location
of this acidic sequence within a molecule central to glu-
cose homeostasis, the correspondence with experimen-
tally measured stoichiometry and conservation across
multiple species, we speculate that this sequence, or a frag-
ment from this acid rich region may give rise to Cr-peptide
fractions isolated from tissue. This suggestion implies that
such fractions may not be homogeneous, discrete Cr(III)
complexes, i.e. proteolysis may lead to a group of similar
peptides that differ by one or more amino acid residues
on either side of the Cr binding site. This interpretation
differs significantly from reports on the isolation of
LMWCr, which attempt to avoid a proteolytic product.
A crystal or solution structure of this region of the insulin
receptor has not been determined. However, the crystal
structure of a homologous molecule, the insulin-like
growth factor receptor (IGR1, GeneID: 124240) has been
published [30,31]. Sequence alignment shows that this
molecule exhibits a conserved difference in this region,
Table 1: Multiple sequence alignment showing conservation of the EDGEECDCGE motif in all known mammalian forms of ADAM19 
and a homologous putative ADAM in fission yeast (top). Multiple sequence alignment showing proposed Cr(III) binding sequence, 
NKDDNEECGD, conserved in the insulin receptor (INSR) across species, but not in the insulin-like growth factor receptor (IG1R) 
(bottom).
SwissProt Protein Species Sequence
Q9H013 ADAM19 Human GNGYLEDGEECDCGEEEECNNP
O35674 ADAM19 Mouse GNGYLEDGEECDCGEEEECNNP
ADAM19 Rat GNGYLEDGEECDCGEEDECKNP
O13766 Homolog S. Pombe GNGIVEDGEECDCGEDCENNP
C
P15208 INSR Mouse NKDDNEECGDVCPGT
P15127 INSR Rat NKDDNEECGDVCPGT
P06213 INSR Human NKDDNEECGDICPGT
Q9PVZ4 Homolog Xenopus NRDNKEECGDVCPGT
Q60751 IG1R Mouse NKPPKECGDLCPGTL
P24062 IG1R Rat NKPPKECGDLCPGTL
P08069 IG1R Human NKPPKECGDLCPGTL
O73798 Homolog Xenopus NKPPKECVDLCPGA.
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having the subsequence -KECGD- in the same region
instead of -EECGD- as found in INSR. The decameric
"acidic region" found in INSR is not present in this growth
factor receptor – cf. -NKPPKECGDLCPGTL-. The cysteine
in -KECGD- forms a disulfide bond with another cysteine
residue 28 positions away in the crystal structure. How-
ever, we do not know if this is due to the crystallization
conditions or representative of the natural form. Further,
the insulin receptor possesses 3 additional cysteine resi-
dues compared to the insulin-like growth factor receptor,
thus the pattern of pairing of cysteine residues to form
disulfide bonds may be different in the two receptor types.
The observed difference may be great enough to preclude
Cr(III) acting on the insulin-like growth factor receptor.
Chromium-peptide complex synthesis
The identified sequence in hand, we synthesized the pen-
tapeptide (AcEECGD-CONH2) and generated the
disulfide-linked dimer via air oxidation. This peptide was
subjected to conditions for the reconstitution of apo-
LMWCr to generate a holo-peptide complex. Incubation
of the peptide with fresh solutions of CrCl3 results in a
clear gray-green solutions of a Cr-peptide complex with
visible electronic spectra (Figure 2) consistent with those
reported for LMWCr [24]. Further, EPR experiments with
Cr-peptide complexes generated from (AcEECGD-
CONH2)2 and (AcNEECGD-CONH2)2 indicate that Cr
exists in trinuclear arrays in these complexes. A prelimi-
nary spectrum is shown in Figure 2 consistent with that of
isolated LMWCr fractions [32], further characterization is
necessary to identify the exact nature of the complexes in
these experiments.
Discussion
Barring the discovery of a novel, unsequenced or uniden-
tified protein or peptide, these data point to the possible
sequence of LMWCr fractions and may point to new
strategies in therapeutic design. In addition, the question
of sequence specificity in Cr(III)-peptide complexes must
be fully addressed, along with thermodynamic and kinetic
aspects of Cr(III) binding and transfer.
Models of non-toxicological action of Cr(III) in biological
systems may broadly fall into three categories: structural,
redox, and iron homeostasis. The earliest models [12],
and those advanced by Vincent [18], fall into a structural
category and focus on the interactions of Cr(III) with pep-
tides and proteins to affect insulin signaling and glucose
metabolism, either directly or indirectly. There is an
important redox model recently advanced [33] that sug-
gests higher oxidation states of Cr interact with tyrosine
phosphatases to inhibit the down-regulation of the insu-
lin receptor. Finally, the chemical similarity of the Cr(III)
and Fe(III) cations, and various in vitro studies suggest that
Cr(III) replacement in the physiological iron transport
and storage apparatus may lead to some small beneficial
outcome for certain diseases [10]. The biological
relevance of these models, and of in vitro experiments
(including our own) may be finally ascertained only after
the fact.
Although unexpected, the results in this report and a crit-
ical review of other literature [9,11-18], suggest that an
extracellular model for Cr(III) biochemistry with respect to
insulin signaling may be plausible (see Supporting Infor-
mation). Such a structural model would include the
known aspects of INSR cycling and insulin degradation
[34], and include the proposed interactions between
Cr(III) and the INSR at the acidic site identified by our
genomic search. This model is reminiscent of Mertz and
co-workers' original proposal [12] of a ternary interaction
between Cr(III), insulin and insulin receptor. It is substan-
tially different from intracellular mechanisms for LMWCr
action [16,18], redox mechanisms [33], and the iron
homeostasis model [10]. In addition, the cycling of the
insulin receptor and insulin degradation [34] may satisfy
the problems of cellular distribution of Cr(III) and
production of LMWCr via proteolysis. Experimentally
observed insulin potentiating activity of Cr(III) may result
from binding to the alpha subunit or bridging interaction
between the two α subunits of an intact INSR molecule.
This model is a parsimonious alternative to current pro-
posals of Cr action in the insulin signaling pathway. How-
ever, this model points directly back to significant kinetic
and a thermodynamic questions about Cr(III) in biologi-
cal systems. For instance, what is the physical form of Cr
in the bloodstream? How is Cr(III) transported and
exchanged between ligands in the serum? Is transport spe-
cific? What structure/activity relationship exists in Cr(III)
complexes to allow their transport across biological mem-
branes? Thermodynamically, a hydrolyzed, multinuclear
Cr cluster should predominate at neutral pH, but trans-
port by transferrin would presumably be in the mononu-
clear Fe binding sites. Alternatively, Cr(III) clusters may be
transported non-specifically in serum by proteins, possi-
bly including transferrin and serum albumin. At this
point, there exist significant gaps in understanding the
possible biochemistry of Cr(III) and what molecular proc-
esses it may affect.
The proposed extracellular model of Cr(III) action in this
report is upstream of IRS1, a therapeutic target of White
and others [7,8], and may lend itself to small-molecule
therapeutic strategies for diabetes and other metabolic
conditions [1]. We hope this model may pave the way for
innovative experiments, better models of Cr(III) bio-
chemistry and excretion, and further understanding of sig-
naling events in complex biochemical pathways.
BMC Chemical Biology 2004, 4:2 http://www.biomedcentral.com/1472-6769/4/2
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Schematic of proposed Cr-peptide complexFigure 2
Schematic of proposed Cr-peptide complex. The EPR spectrum (top) is comparable to that of isolated LMWCr with g ~2.0; 
the spectrum also includes additional hyperfine coupling. Visible absorption spectra of complex formation from the reconstitu-
tion of apo-peptide with fresh solutions of chromium chloride (bottom). These data are qualitative and may comprise more 
than one discreet species.
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Conclusions
A bioinformatic search for an acidic decameric sequence
matching reported stoichiometries of LMWCr amino acid
composition indicates that the peptide may not be a con-
tiguous sequence. An expanded search localized a penta-
meric sequence in the insulin receptor and suggests a
possible identity for the Cr(III)-containing peptide frac-
tions derived from liver. Disulfide linked penta- and hex-
americ peptides based on the identified sequence bind
Cr(III) in a similar fashion to LMWCr fractions reported
in the literature.
Methods
Search for LMWCr
The nr database was downloaded and Perl scripts used to
search for exact matches corresponding to all unique per-
mutations of EEEEGGCCDD. In a separate search, a set of
78 unique protein sequences from Swiss-Prot were
obtained as a result of using the query "insulin human."
This set was searched for exact matches corresponding to
all unique permutations of EEGCD. In addition, the
human proteome was also downloaded and searched for
matches to the same set of pentameric peptides.
N-Acetylglutamylglutamylcysteinylglycylaspartyl 
carboxamide (AcEECGD-CONH2)
The peptide, AcEECGD-CONH2, was synthesized by con-
tinuous-flow automated solid-phase synthesis on a
Perseptive Biosystems Pioneer Peptide Synthesis System.
Peptide synthesis was performed by using standard Fmoc-
protection strategies with TBTU/DIEA activation strategy.
Typically, a 0.5 mmol scale, using Rink amide resin (load-
ing ~0.65 mmol/g) and four times excess of the other rea-
gents (TBTU, protected amino acid) were used. After the
solid-phase synthesis was complete, acetylation at the
amino terminus was carried out for 2 hours (50:50:1:: ace-
tic anhydride:dimethylformamide:pyridine), and the
resulting peptide cleaved from the resin. The peptide was
cleaved from the solid phase resin by adding a slurry of
94% trifluoroacetic acid, 2.5% of water, 2.5% of ethan-
edithiol, and 1% of triisopropylsilane to the reaction ves-
sel and shaking it for 5 h. The trifluoroacetic acid,
containing the peptide, was filtered off by vacuum, and
the resin was washed 2–3 times with trifluoroacetic acid.
The filtrate was evaporated under nitrogen gas until the
volume was reduced to 15 mL. 30 mL of ice-cold diethyl
ether was added to the filtrate, causing the peptide to pre-
cipitate, and the mixture centrifuged to form a pellet of
the peptide. The diethyl ether was decanted and the pep-
tide pellet was washed with diethyl ether three times.
Finally, the peptide was dissolved in 20 mL water contain-
ing 0.1% trifluoroacetic acid and extracted with diethyl
ether three times. The aqueous portion was collected and
freeze-dried to give the synthetic peptide. AcEECGD-
CONH2, has a retention time of 5.3 minutes on a 250 mm
× 4.5 mm C-18 reversed phase HPLC column using a gra-
dient of 5 to 20% acetonitrile in 0.1% trifluoroacetic acid/
water mobile phase running at 1 mL per minute and
detected at a wavelength of 220 nm.
N-
Acetylglutamylglutamylcystinylglycylaspartylcarboxamide 
dimer ((AcEECGD-CONH2)2)
The synthetic peptide, AcEECGD-CONH2, was dissolved
to 10 mg/mL in a 0.1 M solution of ammonium carbonate
at pH 7 and allowed to oxidize under ambient air for 48
hours. The product was isolated by lyophilization and
analyzed by HPLC. The disulfide peptide dimer,
(AcEECGD-CONH2)2, has a retention time of 6.0 minutes
using the above conditions. The product, (AcEECGD-
CONH2)2, has a calculated mass of 1183.35141 and
exhibits a mass of 1183.3477 Daltons when analyzed by
electrospray mass spectrometry.
Chromium N-
acetylglutamylglutamylcystinylglycylaspartylcarboxamide 
(Cr3O(AcEECGD-CONH2)2)
Fifteen milligrams of (AcEECGD-CONH2)2 was weighed
and dissolved in 30 mL of water. A portion of this solution
(5 mL) was taken up in a 25 mL tube, and 4 equivalents
of chromium(III) chloride were added as a solid or in an
aqueous solution. The reaction of the two components
took several minutes and was monitored by ultraviolet-
visible spectrophotometry. The chromium peptide com-
plex, Cr3O(AcEECGD-CONH2)2, exhibits characteristic
spectral absorbance features at 432 nm and 615 nm. The
features are consistent with chromium bound to oxygen
atom donors and similar to the reported spectrum of
LMWCr [24,32]. EPR spectra were collected using the fol-
lowing parameters: microwave frequency, 9.632 GHz;
microwave power incident to the cavity, 2 mW; tempera-
ture, 10 K (LHe cryostat). Samples were prepared by incu-
bating a solution of peptide with chromium chloride at a
final concentration of 1 mM in metal with excess peptide.
The complete characterization (EPR, MS, etc.) of this and
analogous Cr-peptide complexes will be reported
elsewhere.
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